Rangram Chandran, MD
Ophthalmology · Modesto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 29 years
- Baylor College of Medicine, 1997
Offices
1 location
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chandran’s office at (209) 572-2020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A81157 · Current
Licensed to practise in California · since 2002 · expires 2028-02-29 · Baylor College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$1,355,210
Medicare paid this office $1,355,210 for 846 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 118 | $474,217 | $136 |
| Established patient complete exam of visual system | 794 | $195,177 | $101 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 694 | $166,393 | $143 |
| Injection of drug into eye | 194 | $133,866 | $94 |
| Injection, aflibercept, 1 mg | 12 | $105,288 | None |
See all 16 services
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 118 | $474,217 | $136 |
| Established patient complete exam of visual system | 794 | $195,177 | $101 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 694 | $166,393 | $143 |
| Injection of drug into eye | 194 | $133,866 | $94 |
| Injection, aflibercept, 1 mg | 12 | $105,288 | None |
| Unclassified biologics | 62 | $90,134 | None |
| Compounded drug, not otherwise classified | 156 | $39,010 | None |
| Photography of the retina | 752 | $38,702 | $30 |
| Imaging of retina | 500 | $36,346 | $34 |
| Destruction of growth of retina using a laser | 32 | $19,887 | $423 |
| New patient complete exam of visual system | 154 | $17,544 | $114 |
| Destruction of leaking blood vessels of retina using laser | 22 | $11,588 | $290 |
| Photocoagulation treatment to prevent detachment of retina | 12 | $2,965 | $212 |
| Established patient problem focused exam of visual system | 25 | $2,744 | $65 |
| Injection, bevacizumab, 10 mg | 20 | $1,258 | None |
| 2d ultrasound scan of eye tissue and structures | 12 | $750 | $38 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | 948 | 1,063 | 1,152 | 1,240 | 1,272 | 1,428 |
| Destruction of leaking blood vessels of retina using laser | 100 | 105 | 61 | 53 | 37 | 40 |
| Destruction of growth of retina using a laser | 73 | 87 | 79 | 53 | 43 | 47 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 27 | 21 | – | 13 | – | – |
| Photocoagulation treatment to prevent detachment of retina | – | – | – | – | – | 14 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | – | – | – | – | 14 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
846 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 18% · Women 58% · Also on Medicaid 20% · Health risk score 1.40. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 47% · Chronic kidney disease 33% · Coronary heart disease 29% · Atrial fibrillation 19% · Heart failure 15% · Cancer 14% · Depression 14% · COPD 12% · Stroke 9% · Dementia 6%.
The office billed $3,815,041, Medicare allowed $1,739,873 and paid $1,355,210; for 11,566 services of 31 kinds; $580,770 of it was for drugs given in the office and $774,440 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 846 | 11,566 | 76 | 1.40 | $3,815,041 | $1,355,210 |
| 2023 | 824 | 11,352 | 76 | 1.34 | $3,761,443 | $1,381,368 |
| 2022 | 796 | 8,460 | 76 | 1.39 | $2,112,677 | $794,501 |
| 2021 | 775 | 8,221 | 76 | 1.49 | $1,951,727 | $720,053 |
| 2020 | 740 | 7,927 | 76 | 1.64 | $2,223,284 | $854,069 |
| 2019 | 752 | 8,066 | 76 | 1.61 | $2,211,480 | $866,342 |
| 2018 | 756 | 7,895 | 76 | 1.73 | $1,935,686 | $771,007 |
| 2017 | 816 | 8,279 | 75 | 1.65 | $1,985,883 | $825,569 |
| 2016 | 832 | 9,226 | 75 | 1.63 | $2,335,900 | $967,483 |
| 2015 | 849 | 9,232 | 74 | 1.66 | $2,509,707 | $1,033,371 |
| 2014 | 893 | 8,583 | 75 | 1.58 | $2,550,349 | $935,474 |
| 2013 | 821 | 8,515 | 75 | 1.56 | $2,522,685 | $851,882 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 117 | $721,610 | $171 |
| Established patient complete exam of visual system | 756 | $171,028 | $97 |
| Injection of drug into eye | 168 | $115,548 | $91 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 675 | $113,558 | $113 |
| Injection, aflibercept, 1 mg | 16 | $80,613 | None |
| Imaging of retina | 484 | $35,715 | $33 |
| Photography of the retina | 715 | $31,500 | $29 |
| Compounded drug, not otherwise classified | 111 | $21,011 | None |
| Destruction of growth of retina using a laser | 28 | $18,283 | $425 |
| New patient complete exam of visual system | 152 | $17,673 | $116 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 11 | $13,694 | $978 |
| Destruction of leaking blood vessels of retina using laser | 18 | $10,415 | $281 |
| Established patient problem focused exam of visual system | 30 | $2,703 | $60 |
| Injection, bevacizumab, 10 mg | 27 | $2,480 | None |
| 2d ultrasound scan of eye tissue and structures | 27 | $2,129 | $39 |
2022: 13 services
| Established patient complete exam of visual system | 726 | $170,826 | $96 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 700 | $140,061 | $102 |
| Injection of drug into eye | 182 | $111,152 | $90 |
| Compounded drug, not otherwise classified | 168 | $74,872 | None |
| Photography of the retina | 722 | $40,971 | $29 |
| Imaging of retina | 372 | $25,874 | $32 |
| Destruction of growth of retina using a laser | 30 | $22,393 | $423 |
| New patient complete exam of visual system | 178 | $19,412 | $109 |
| Destruction of leaking blood vessels of retina using laser | 26 | $14,722 | $278 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 13 | $5,782 | $445 |
| Established patient problem focused exam of visual system | 33 | $3,512 | $66 |
| Injection, bevacizumab, 10 mg | 52 | $3,437 | None |
| 2d ultrasound scan of eye tissue and structures | 16 | $1,060 | $38 |
2021: 13 services
| Established patient complete exam of visual system | 714 | $181,317 | $98 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 674 | $133,119 | $99 |
| Injection of drug into eye | 181 | $106,741 | $93 |
| Compounded drug, not otherwise classified | 177 | $74,533 | None |
| Injection, aflibercept, 1 mg | 16 | $50,323 | None |
| Photography of the retina | 709 | $42,080 | $29 |
| Destruction of growth of retina using a laser | 45 | $33,353 | $422 |
| Imaging of retina | 373 | $26,699 | $34 |
| Destruction of leaking blood vessels of retina using laser | 26 | $16,815 | $276 |
| New patient complete exam of visual system | 139 | $16,268 | $117 |
| Established patient problem focused exam of visual system | 54 | $4,989 | $68 |
| Injection, bevacizumab, 10 mg | 57 | $4,577 | None |
| 2d ultrasound scan of eye tissue and structures | 15 | $975 | $41 |
2020: 15 services
| Injection, aflibercept, 1 mg | 17 | $215,074 | None |
| Established patient complete exam of visual system | 678 | $162,779 | $97 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 651 | $115,683 | $87 |
| Injection of drug into eye | 178 | $89,066 | $84 |
| Compounded drug, not otherwise classified | 165 | $65,509 | None |
| Photography of the retina | 702 | $50,111 | $34 |
| Destruction of growth of retina using a laser | 54 | $37,802 | $435 |
| Destruction of leaking blood vessels of retina using laser | 44 | $29,795 | $284 |
| Imaging of retina | 307 | $23,192 | $34 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 18 | $9,556 | $455 |
| New patient visit (45+ min) | 70 | $9,051 | $129 |
| New patient complete exam of visual system | 62 | $7,184 | $116 |
| Established patient problem focused exam of visual system | 29 | $2,695 | $67 |
| 2d ultrasound scan of eye tissue and structures | 14 | $1,500 | $45 |
| Injection, bevacizumab, 10 mg | 11 | $1,347 | None |
2019: 15 services
| Injection, aflibercept, 1 mg | 28 | $234,625 | None |
| Established patient complete exam of visual system | 675 | $176,346 | $100 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 645 | $97,456 | $77 |
| Injection of drug into eye | 185 | $77,116 | $81 |
| Photography of the retina | 696 | $62,741 | $39 |
| Compounded drug, not otherwise classified | 176 | $49,443 | None |
| Destruction of growth of retina using a laser | 47 | $31,094 | $426 |
| Destruction of leaking blood vessels of retina using laser | 38 | $28,372 | $284 |
| Imaging of retina | 333 | $26,107 | $34 |
| New patient visit (45+ min) | 129 | $15,949 | $124 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 23 | $12,221 | $453 |
| Established patient problem focused exam of visual system | 47 | $4,408 | $63 |
| 2d ultrasound scan of eye tissue and structures | 30 | $4,068 | $51 |
| New patient complete exam of visual system | 15 | $1,574 | $105 |
| Exam of visual field with extended testing | 27 | $1,287 | $48 |
2018: 15 services
| Injection, aflibercept, 1 mg | 14 | $168,279 | None |
| Established patient complete exam of visual system | 676 | $158,301 | $97 |
| Injection of drug into eye | 194 | $91,963 | $81 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 643 | $85,940 | $71 |
| Photography of the retina | 673 | $61,566 | $43 |
| Compounded drug, not otherwise classified | 176 | $59,886 | None |
| Destruction of growth of retina using a laser | 49 | $36,811 | $428 |
| Destruction of leaking blood vessels of retina using laser | 32 | $24,741 | $284 |
| Imaging of retina | 322 | $22,568 | $33 |
| New patient visit (45+ min) | 114 | $13,491 | $118 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 14 | $7,123 | $445 |
| Established patient problem focused exam of visual system | 43 | $4,944 | $62 |
| 2d ultrasound scan of eye tissue and structures | 30 | $3,768 | $62 |
| Exam of visual field with extended testing | 24 | $1,245 | $52 |
| Injection, bevacizumab, 10 mg | 11 | $883 | None |
2017: 16 services
| Injection, aflibercept, 1 mg | 12 | $192,952 | None |
| Established patient complete exam of visual system | 723 | $139,849 | $93 |
| Injection of drug into eye | 219 | $113,707 | $82 |
| Photography of the retina | 705 | $78,722 | $54 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 678 | $77,140 | $64 |
| Compounded drug, not otherwise classified | 203 | $70,565 | None |
| Destruction of growth of retina using a laser | 57 | $39,499 | $425 |
| Destruction of leaking blood vessels of retina using laser | 49 | $31,732 | $271 |
| New patient visit (45+ min) | 157 | $17,880 | $114 |
| Imaging of retina | 330 | $17,502 | $33 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 12 | $7,400 | $435 |
| Established patient problem focused exam of visual system | 45 | $4,698 | $59 |
| 2d ultrasound scan of eye tissue and structures | 24 | $3,837 | $74 |
| Injection, bevacizumab, 10 mg | 15 | $1,116 | None |
| New patient complete exam of visual system | 13 | $1,110 | $85 |
| Exam of visual field with extended testing | 15 | $813 | $54 |
2016: 16 services
| Exam of retinal blood vessels using a special camera after injection of a dye | 675 | $211,488 | $86 |
| Established patient complete exam of visual system | 717 | $138,860 | $91 |
| Injection of drug into eye | 200 | $99,923 | $81 |
| Photography of the retina | 685 | $79,586 | $58 |
| Compounded drug, not otherwise classified | 188 | $56,792 | None |
| Destruction of growth of retina using a laser | 75 | $46,856 | $415 |
| Imaging of retina | 335 | $22,740 | $36 |
| New patient visit (45+ min) | 157 | $18,786 | $120 |
| Destruction of leaking blood vessels of retina using laser | 36 | $12,708 | $259 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 35 | $9,926 | $216 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 16 | $7,989 | $444 |
| Established patient problem focused exam of visual system | 37 | $4,011 | $65 |
| New patient complete exam of visual system | 29 | $2,719 | $94 |
| Injection, bevacizumab, 10 mg | 36 | $2,447 | None |
| 2d ultrasound scan of eye tissue and structures | 20 | $2,077 | $72 |
| Imaging of optic nerve | 11 | $433 | $36 |
2015: 19 services
| Exam of retinal blood vessels using a special camera after injection of a dye | 679 | $214,312 | $87 |
| Injection, aflibercept, 1 mg | 12 | $162,758 | None |
| Established patient complete exam of visual system | 735 | $144,924 | $92 |
| Injection of drug into eye | 195 | $91,187 | $82 |
| Photography of the retina | 688 | $83,691 | $58 |
| Destruction of leaking blood vessels of retina using laser | 45 | $61,082 | $804 |
| Destruction of growth of retina using a laser | 61 | $48,559 | $422 |
| Unclassified biologics | 165 | $37,912 | None |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 14 | $24,784 | $1,304 |
| Imaging of retina | 331 | $23,560 | $37 |
| New patient visit (45+ min) | 179 | $22,230 | $124 |
| Compounded Drug, Not Otherwise Classified | 111 | $12,278 | $55 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 19 | $8,898 | $445 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 31 | $7,749 | $215 |
| 2d ultrasound scan of eye tissue and structures | 41 | $6,447 | $77 |
| Established patient problem focused exam of visual system | 36 | $3,467 | $65 |
| New patient complete exam of visual system | 20 | $1,962 | $98 |
| Injection, bevacizumab, 10 mg | 27 | $1,873 | None |
| Imaging of optic nerve | 22 | $795 | $36 |
2014: 19 services
| Injection, aflibercept, 1 mg | 15 | $157,437 | None |
| Established patient complete exam of visual system | 784 | $154,261 | $95 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 675 | $119,362 | $90 |
| Injection of drug into eye | 230 | $100,183 | $82 |
| Photography of the retina | 702 | $87,382 | $58 |
| Destruction of growth of retina using a laser | 86 | $64,319 | $423 |
| Destruction of leaking blood vessels of retina using laser | 50 | $63,218 | $832 |
| Unclassified biologics | 216 | $41,463 | None |
| Imaging of retina | 310 | $25,007 | $37 |
| New patient visit (45+ min) | 162 | $19,698 | $122 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 34 | $9,985 | $208 |
| 2d ultrasound scan of eye tissue and structures | 43 | $7,600 | $78 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 16 | $7,148 | $447 |
| Training for self-care or home management, each 15 minutes | 23 | $3,061 | $22 |
| New patient complete exam of visual system | 22 | $2,432 | $111 |
| Established patient problem focused exam of visual system | 24 | $2,118 | $66 |
| Injection, bevacizumab, 10 mg | 14 | $1,454 | None |
| Exam of visual field with extended testing | 18 | $781 | $43 |
| Short return visit | 13 | $573 | $36 |
2013: 19 services
| Established patient complete exam of visual system | 722 | $141,145 | $97 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 647 | $115,250 | $93 |
| Injection of drug into eye | 232 | $110,865 | $82 |
| Photography of the retina | 654 | $82,136 | $58 |
| Destruction of growth of retina using a laser | 96 | $63,420 | $426 |
| Destruction of leaking blood vessels of retina using laser | 44 | $57,558 | $834 |
| Unclassified biologics | 228 | $49,025 | None |
| Imaging of retina | 308 | $25,268 | $36 |
| New patient visit (45+ min) | 123 | $15,744 | $128 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 42 | $13,554 | $176 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 22 | $12,706 | $454 |
| Removal of membrane of retina | 11 | $12,202 | $1,109 |
| 2d ultrasound scan of eye tissue and structures | 39 | $6,412 | $78 |
| Training for self-care or home management, each 15 minutes | 24 | $3,804 | $23 |
| Established patient problem focused exam of visual system | 18 | $2,784 | $68 |
| Injection, bevacizumab, 10 mg | 20 | $1,583 | None |
| New patient complete exam of visual system | 15 | $1,569 | $105 |
| Exam of visual field with extended testing | 17 | $945 | $56 |
| Short return visit | 11 | $470 | $36 |
Medicaid work
$23,674 in 2024
Medicaid paid $23,674 for 738 billed services this clinician did in 2024, up to 33 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 153 | $9,643 |
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 43 | $7,240 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 208 | $2,712 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 124 | $2,195 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 145 | $1,154 |
| Injection, bevacizumab, 10 mg | 13 | $435 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 52 | $295 |
| 2024 | 738 | 7 | 33 | $23,674 |
| 2023 | 693 | 5 | 29 | $8,524 |
| 2022 | 341 | 5 | 22 | $3,878 |
| 2021 | 510 | 6 | 26 | $7,075 |
| 2020 | 283 | 6 | 17 | $2,499 |
| 2019 | 359 | 6 | 18 | $1,898 |
| 2018 | 377 | 4 | 22 | $2,293 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 99 | $3,832 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 246 | $1,878 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 123 | $1,745 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 122 | $762 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 103 | $307 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 65 | $1,973 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 125 | $753 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 61 | $543 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 64 | $368 |
| Compounded drug, not otherwise classified | 26 | $241 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 188 | $4,459 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 67 | $841 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 124 | $696 |
| Compounded drug, not otherwise classified | 35 | $572 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 83 | $507 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 13 | $0 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 115 | $1,411 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 54 | $525 |
| Compounded drug, not otherwise classified | 44 | $357 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 29 | $102 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 29 | $58 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 12 | $46 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 91 | $1,062 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 129 | $368 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 56 | $260 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 40 | $147 |
| Compounded drug, not otherwise classified | 31 | $56 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 12 | $4 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 166 | $1,784 |
| Compounded drug, not otherwise classified | 120 | $409 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 62 | $82 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 29 | $19 |
Drugs they prescribed that Part D paid
$40,924
Pharmacies billed $40,924 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
649 generic and 431 brand-name prescriptions · $40,924 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 154 | $9,189 | $60 |
| Restasis Multidose | 13 | $7,579 | $583 |
| Latanoprost | 388 | $5,522 | $14 |
| Timolol Maleate | 230 | $3,803 | $17 |
| Ofloxacin | 71 | $1,127 | $16 |
See all 12 drugs
| Prednisolone Acetate | 154 | $9,189 | $60 |
| Restasis Multidose | 13 | $7,579 | $583 |
| Latanoprost | 388 | $5,522 | $14 |
| Timolol Maleate | 230 | $3,803 | $17 |
| Ofloxacin | 71 | $1,127 | $16 |
| Ketorolac Tromethamine | 25 | $960 | $38 |
| Dorzolamide | 20 | $711 | $36 |
| Dorzolamide-Timolol | 38 | $570 | $15 |
| Brimonidine | 31 | $502 | $16 |
| Azelastine | 22 | $331 | $15 |
| Prednisone | 11 | $275 | $25 |
| Diazepam | 17 | $18 | $1 |
Year by year
| 2024 | 1,080 | 244 | None | 40% | $40,924 |
| 2023 | 1,118 | 258 | None | 43% | $57,461 |
| 2022 | 1,108 | 252 | 1% (12) | 41% | $61,626 |
| 2021 | 1,065 | 246 | None | 42% | $58,406 |
| 2020 | 1,146 | 242 | 1% (11) | 41% | $62,069 |
| 2019 | 1,127 | 236 | 1% (11) | 33% | $62,617 |
| 2018 | 1,134 | 214 | 1% (16) | 36% | $63,222 |
| 2017 | 1,079 | 205 | 2% (20) | 34% | $57,181 |
| 2016 | 967 | 223 | 4% (40) | None | $51,056 |
| 2015 | 1,057 | 274 | 8% (86) | None | $62,218 |
| 2014 | 1,394 | 415 | 5% (73) | 32% | $66,807 |
| 2013 | 1,339 | 450 | 7% (98) | 30% | $43,727 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Prednisolone Acetate | 180 | $12,321 | $68 |
| Restasis | 11 | $12,191 | $1,108 |
| Latanoprost | 397 | $10,642 | $27 |
| Timolol Maleate | 223 | $4,574 | $21 |
| Ofloxacin | 101 | $2,483 | $25 |
| Brimonidine | 43 | $1,132 | $26 |
| Dorzolamide | 23 | $1,109 | $48 |
| Dorzolamide-Timolol | 25 | $898 | $36 |
| Ketorolac Tromethamine | 18 | $667 | $37 |
| Azelastine | 16 | $551 | $34 |
| Prednisone | 15 | $432 | $29 |
| Diazepam | 18 | $17 | $1 |
2022: 14 drugs
| Prednisolone Acetate | 157 | $12,150 | $77 |
| Latanoprost | 438 | $11,716 | $27 |
| Brinzolamide | 12 | $6,955 | $580 |
| Timolol Maleate | 224 | $5,583 | $25 |
| Brimonidine | 23 | $2,401 | $104 |
| Ofloxacin | 83 | $1,635 | $20 |
| Ketorolac Tromethamine | 19 | $1,548 | $81 |
| Dorzolamide | 21 | $1,321 | $63 |
| Atropine Sulfate | 16 | $1,121 | $70 |
| Dorzolamide-Timolol | 17 | $861 | $51 |
| Azelastine | 17 | $340 | $20 |
| Prednisone | 15 | $270 | $18 |
| Hydrocodone-Acetaminophen | 12 | $46 | $4 |
| Diazepam | 11 | $14 | $1 |
2021: 13 drugs
| Latanoprost | 354 | $12,125 | $34 |
| Prednisolone Acetate | 164 | $11,428 | $70 |
| Restasis | 13 | $10,150 | $781 |
| Timolol Maleate | 226 | $5,035 | $22 |
| Brimonidine | 30 | $3,445 | $115 |
| Atropine Sulfate | 25 | $1,604 | $64 |
| Ofloxacin | 77 | $1,489 | $19 |
| Dorzolamide-Timolol | 20 | $1,459 | $73 |
| Dorzolamide | 19 | $1,137 | $60 |
| Ketorolac Tromethamine | 25 | $839 | $34 |
| Prednisone | 40 | $626 | $16 |
| Azelastine | 12 | $152 | $13 |
| Diazepam | 11 | $18 | $2 |
2020: 13 drugs
| Prednisolone Acetate | 188 | $11,913 | $63 |
| Latanoprost | 347 | $9,974 | $29 |
| Travatan Z | 20 | $5,556 | $278 |
| Timolol Maleate | 245 | $4,670 | $19 |
| Brimonidine | 37 | $4,315 | $117 |
| Atropine Sulfate | 39 | $2,069 | $53 |
| Ofloxacin | 87 | $1,561 | $18 |
| Ketorolac Tromethamine | 26 | $1,290 | $50 |
| Dorzolamide | 17 | $771 | $45 |
| Olopatadine | 15 | $546 | $36 |
| Prednisone | 17 | $353 | $21 |
| Hydrocodone-Acetaminophen | 11 | $58 | $5 |
| Diazepam | 17 | $44 | $3 |
2019: 12 drugs
| Latanoprost | 380 | $9,248 | $24 |
| Prednisolone Acetate | 131 | $8,214 | $63 |
| Travatan Z | 18 | $6,036 | $335 |
| Timolol Maleate | 286 | $5,217 | $18 |
| Brimonidine | 39 | $3,912 | $100 |
| Atropine Sulfate | 39 | $1,409 | $36 |
| Ofloxacin | 80 | $1,356 | $17 |
| Ketorolac Tromethamine | 26 | $1,047 | $40 |
| Dorzolamide | 16 | $588 | $37 |
| Prednisone | 13 | $151 | $12 |
| Hydrocodone-Acetaminophen | 11 | $63 | $6 |
| Diazepam | 22 | $38 | $2 |
2018: 14 drugs
| Nevanac | 17 | $12,833 | $755 |
| Travatan Z | 23 | $8,940 | $389 |
| Prednisolone Acetate | 122 | $8,253 | $68 |
| Latanoprost | 407 | $7,758 | $19 |
| Timolol Maleate | 270 | $4,096 | $15 |
| Acetazolamide | 16 | $3,158 | $197 |
| Brimonidine | 52 | $2,460 | $47 |
| Ofloxacin | 71 | $1,562 | $22 |
| Olopatadine | 16 | $1,483 | $93 |
| Ketorolac Tromethamine | 30 | $1,225 | $41 |
| Atropine Sulfate | 17 | $536 | $32 |
| Dorzolamide | 14 | $371 | $27 |
| Prednisone | 11 | $244 | $22 |
| Hydrocodone-Acetaminophen | 16 | $135 | $8 |
2017: 13 drugs
| Nevanac | 16 | $10,502 | $656 |
| Prednisolone Acetate | 122 | $8,458 | $69 |
| Travatan Z | 30 | $8,453 | $282 |
| Latanoprost | 365 | $5,847 | $16 |
| Brimonidine | 32 | $3,912 | $122 |
| Timolol Maleate | 282 | $3,443 | $12 |
| Acetazolamide | 13 | $1,890 | $145 |
| Ofloxacin | 83 | $1,659 | $20 |
| Dorzolamide-Timolol | 18 | $525 | $29 |
| Ketorolac Tromethamine | 14 | $389 | $28 |
| Atropine Sulfate | 11 | $379 | $34 |
| Hydrocodone-Acetaminophen | 20 | $128 | $6 |
| Diazepam | 14 | $32 | $2 |
2016: 16 drugs
| Prednisolone Acetate | 147 | $10,121 | $69 |
| Travatan Z | 35 | $9,765 | $279 |
| Nevanac | 11 | $6,875 | $625 |
| Timolol Maleate | 210 | $3,610 | $17 |
| Latanoprost | 244 | $3,340 | $14 |
| Combigan | 17 | $3,166 | $186 |
| Alphagan P | 13 | $2,938 | $226 |
| Acetazolamide | 16 | $2,342 | $146 |
| Ofloxacin | 100 | $1,810 | $18 |
| Brimonidine | 22 | $1,522 | $69 |
| Atropine Sulfate | 13 | $590 | $45 |
| Prednisone | 18 | $473 | $26 |
| Hydrocodone-Acetaminophen | 39 | $357 | $9 |
| Dorzolamide-Timolol | 13 | $247 | $19 |
| Omeprazole | 11 | $101 | $9 |
| Diazepam | 13 | $44 | $3 |
2015: 12 drugs
| Prednisolone Acetate | 183 | $14,768 | $81 |
| Travatan Z | 59 | $11,814 | $200 |
| Nevanac | 14 | $8,667 | $619 |
| Acetazolamide | 41 | $5,176 | $126 |
| Azopt | 19 | $4,867 | $256 |
| Ofloxacin | 195 | $3,332 | $17 |
| Timolol Maleate | 170 | $2,008 | $12 |
| Latanoprost | 139 | $1,736 | $12 |
| Hydrocodone-Acetaminophen | 86 | $761 | $9 |
| Prednisone | 25 | $618 | $25 |
| Omeprazole | 17 | $235 | $14 |
| Diazepam | 14 | $41 | $3 |
2014: 19 drugs
| Travatan Z | 110 | $19,073 | $173 |
| Prednisolone Acetate | 160 | $9,604 | $60 |
| Alphagan P | 39 | $6,043 | $155 |
| Acetazolamide | 54 | $5,175 | $96 |
| Ofloxacin | 483 | $4,646 | $10 |
| Azopt | 21 | $4,538 | $216 |
| Nevanac | 20 | $3,503 | $175 |
| Vigamox | 30 | $3,287 | $110 |
| Timolol Maleate | 162 | $1,875 | $12 |
| Lumigan | 12 | $1,390 | $116 |
| Bromfenac | 13 | $1,375 | $106 |
| Brimonidine | 16 | $1,073 | $67 |
| Latanoprost | 55 | $834 | $15 |
| Atropine Sulfate | 25 | $617 | $25 |
| Hydrocodone-Acetaminophen | 72 | $549 | $8 |
| Prednisone | 19 | $461 | $24 |
| Ciprofloxacin | 27 | $302 | $11 |
| Omeprazole | 13 | $110 | $8 |
| Diazepam | 15 | $30 | $2 |
2013: 14 drugs
| Travatan Z | 78 | $12,542 | $161 |
| Vigamox | 51 | $5,158 | $101 |
| Ofloxacin | 595 | $4,486 | $8 |
| Alphagan P | 29 | $4,198 | $145 |
| Prednisolone Acetate | 163 | $3,852 | $24 |
| Nevanac | 15 | $2,250 | $150 |
| Timolol Maleate | 122 | $1,210 | $10 |
| Acetazolamide | 12 | $575 | $48 |
| Hydrocodone-Acetaminophen | 96 | $495 | $5 |
| Atropine Sulfate | 20 | $473 | $24 |
| Latanoprost | 27 | $414 | $15 |
| Prednisone | 17 | $393 | $23 |
| Omeprazole | 12 | $104 | $9 |
| Diazepam | 17 | $41 | $2 |
Money from drug and device companies
$361 in 2025
| 2025 | 5 | 8 | None | $361 |
| 2024 | 6 | 12 | None | $468 |
| 2023 | 5 | 13 | None | $367 |
| 2022 | 4 | 6 | None | $195 |
| 2021 | 3 | 8 | None | $160 |
| 2020 | 3 | 4 | None | $99 |
| 2019 | 4 | 11 | None | $435 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Dutch Ophthalmic USA | Eva, Combined Machine | $139 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $100 | 3 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $57 | 2 payments
|
| Astellas Pharma US | Izervay | $35 | 1 payment
|
| Genentech USA | Vabysmo | $29 | 1 payment
|
See all 8 published payments
| Apellis Pharmaceuticals | Meals · 2025-12-09 | Syfovre | $33 |
| Genentech USA | Meals · 2025-11-18 | Vabysmo | $29 |
| Apellis Pharmaceuticals | Meals · 2025-08-28 | Syfovre | $35 |
| ANI Pharmaceuticals | Meals · 2025-08-06 | Iluvien | $28 |
| Dutch Ophthalmic USA | Meals · 2025-04-23 | Eva, Combined Machine | $139 |
| Astellas Pharma US | Meals · 2025-03-05 | Izervay | $35 |
| ANI Pharmaceuticals | Meals · 2025-02-26 | Purified Cortrophin Gel | $29 |
| Apellis Pharmaceuticals | Meals · 2025-02-05 | Syfovre | $32 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $468
| Alimera Sciences | Yutiq | $150 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $130 | 4 payments
|
| Astellas Pharma US | Izervay | $102 | 3 payments
|
| Carl Zeiss Meditec USA | Cirrus Hd-Oct | $44 | 1 payment
|
| Genentech USA | Vabysmo | $22 | 1 payment
|
| Biogen | Byooviz | $21 | 1 payment
|
2023: $367
| Biogen | None | $140 | 6 payments
|
| Astellas Pharma US | None | $90 | 3 payments
|
| Alimera Sciences | Iluvien | $62 | 2 payments
|
| Carl Zeiss Meditec USA | Lumera 700 | $46 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $29 | 1 payment
|
2022: $195
| Alimera Sciences | Iluvien | $99 | 2 payments
|
| Biogen | None | $40 | 2 payments
|
| Genentech USA | Susvimo | $33 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $24 | 1 payment
|
2021: $160
| Mallinckrodt Hospital Products | Acthar | $84 | 4 payments
|
| Alimera Sciences | Iluvien | $58 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea | $19 | 1 payment
|
2020: $99
| Alimera Sciences | Iluvien | $55 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $24 | 1 payment
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $435
| Novartis Pharmaceuticals | Beovu | $262 | 5 payments
|
| Carl Zeiss Meditec | Clarus 500 Fundus Camera | $86 | 1 payment
|
| Alimera Sciences | Iluvien | $70 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $17 | 1 payment
|
Checkups this office reported
8 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 99.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of SurgeryAs Medicare defines this measure | 100% | 21 |
| Checked for fall riskOlder patients screened for fall risk | 88%That's most of the people this applied to. | 1,735 |
| Closing the Referral Loop: Receipt of Specialist ReportAs Medicare defines this measure | 67% | 102 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 100%That's most of the people this applied to. | 489 |
| Diabetic Macular Edema - Loss of Visual AcuityAs Medicare defines this measure | 100% | 99 |
| Glaucoma Intraocular Pressure ReductionAs Medicare defines this measure | 92% | 198 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 92%That's most of the people this applied to. | 869 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 0%That's few of the people this applied to. Better on this measure. | 1,778 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Create and Implement a Language Access Plan
- Did a security review of patient data
- ONC-ACB Surveillance Attestation
- Reports to a public-health or clinical registry
- Exempt from electronic case reporting
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
Professional record
- NPI
- 1194714642
- Licence
- CA A81157California A81157: Current · expires 2028-02-29
- Trained
- Baylor College of Medicine, 1997 · 29 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A811570
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- Po Box 576067, Modesto, CA, 95357
- NPI first listed
- 2005-10-18
- NPI last updated
- 2014-11-28
This is when the NPI record was last certified, not a medical board exam.